Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/43331
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Degtyarev, Evgeny | - |
dc.contributor.author | Bolanos, Natacha | - |
dc.contributor.author | Brody, Joshua D. | - |
dc.contributor.author | Buchbinder, Aby | - |
dc.contributor.author | BUYSE, Marc | - |
dc.contributor.author | Fuchs, Miriam | - |
dc.contributor.author | Halabi, Susan | - |
dc.contributor.author | Hemmings, Robert | - |
dc.contributor.author | Masood, Aisha | - |
dc.contributor.author | Newsome, Simon | - |
dc.contributor.author | Saxton, Claire | - |
dc.contributor.author | Warwick, Lorna | - |
dc.contributor.author | Yateman, Nigel A. | - |
dc.contributor.author | Zuber, Emmanuel | - |
dc.date.accessioned | 2024-07-05T09:04:13Z | - |
dc.date.available | 2024-07-05T09:04:13Z | - |
dc.date.issued | 2024 | - |
dc.date.submitted | 2024-07-05T08:56:38Z | - |
dc.identifier.citation | Future oncology (London. Print), | - |
dc.identifier.uri | http://hdl.handle.net/1942/43331 | - |
dc.description.abstract | We observed lack of clarity and consistency in end point definitions of large randomized clinical trials in diffuse large B-cell lymphoma. These inconsistencies are such that trials might, in fact, address different clinical questions. They complicate interpretation of results, including comparisons across studies. Problems arise from different ways to account for events occurring after randomization including absence of improvement in disease status, treatment discontinuation or the initiation of new therapy. We call for more dialogue between stakeholders to define with clarity the questions of interest and corresponding end points. We illustrate that assessing different end point rules across a range of plausible patient journeys can be a powerful tool to facilitate such a discussion and contribute to better understanding of patient-relevant end points. | - |
dc.description.sponsorship | E Degtyarev, A Buchbinder, M Fuchs, A Masood, S Newsome,N Yateman and E Zuber are employees and stock owners ofNovartis. C Saxton is a co-principal investigator on a study thatwas funded by Bristol Myers Squibb and Blue Note Therapeu-tics. The authors who represent Cancer Support Communityand Lymphoma Coalition did not receive any compensation fortheir work on this manuscript. The authors have no other rele-vant affiliations or financial involvement with any organizationor entity with a financial interest in or financial conflict with thesubject matter or materials discussed in the manuscript apartfrom those disclosed. | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.rights | 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis GroupThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License(http://creativecommons.org/licenses/by- nc- nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properlycited and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by theauthor(s) or with their consent. | - |
dc.subject.other | estimand framework | - |
dc.subject.other | event-free survival | - |
dc.subject.other | non-Hodgkin lymphoma | - |
dc.subject.other | overall survival | - |
dc.subject.other | patient-reported outcomes | - |
dc.subject.other | patient journeys | - |
dc.subject.other | progression-free survival | - |
dc.subject.other | treatment effects | - |
dc.title | End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue? | - |
dc.type | Journal Contribution | - |
local.format.pages | 15 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Degtyarev, E (corresponding author), Novartis Pharm, Basel, Switzerland. | - |
dc.description.notes | evgeny.degtyarev@novartis.com | - |
local.publisher.place | 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.bibliographicCitation.status | Early view | - |
dc.identifier.doi | 10.1080/14796694.2024.2357537 | - |
dc.identifier.pmid | 38889345 | - |
dc.identifier.isi | 001250729700001 | - |
dc.contributor.orcid | Halabi, Susan/0000-0003-4135-2777 | - |
local.provider.type | wosris | - |
local.description.affiliation | [Degtyarev, Evgeny; Fuchs, Miriam; Newsome, Simon; Yateman, Nigel A.; Zuber, Emmanuel] Novartis Pharm, Basel, Switzerland. | - |
local.description.affiliation | [Bolanos, Natacha] Lymphoma Coalit, Madrid, Spain. | - |
local.description.affiliation | [Brody, Joshua D.] Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY USA. | - |
local.description.affiliation | [Buchbinder, Aby; Masood, Aisha] Novartis Pharmaceut, E Hanover, NJ USA. | - |
local.description.affiliation | [Buyse, Marc] Int Drug Dev Inst IDDI, Louvain La Neuve, Belgium. | - |
local.description.affiliation | [Buyse, Marc] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformatics 1 Bio, Diepenbeek, Belgium. | - |
local.description.affiliation | [Halabi, Susan] Duke Clin Res Inst, Durham, NC USA. | - |
local.description.affiliation | [Halabi, Susan] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC USA. | - |
local.description.affiliation | [Hemmings, Robert] CONSILIUM Salmonson & Hemmings, Woking, England. | - |
local.description.affiliation | [Saxton, Claire] Canc Support Community, Washington, DC USA. | - |
local.description.affiliation | [Warwick, Lorna] Lymphoma Coalit, Management, Mississauga, ON, Canada. | - |
local.uhasselt.international | yes | - |
item.fullcitation | Degtyarev, Evgeny; Bolanos, Natacha; Brody, Joshua D.; Buchbinder, Aby; BUYSE, Marc; Fuchs, Miriam; Halabi, Susan; Hemmings, Robert; Masood, Aisha; Newsome, Simon; Saxton, Claire; Warwick, Lorna; Yateman, Nigel A. & Zuber, Emmanuel (2024) End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?. In: Future oncology (London. Print),. | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.contributor | Degtyarev, Evgeny | - |
item.contributor | Bolanos, Natacha | - |
item.contributor | Brody, Joshua D. | - |
item.contributor | Buchbinder, Aby | - |
item.contributor | BUYSE, Marc | - |
item.contributor | Fuchs, Miriam | - |
item.contributor | Halabi, Susan | - |
item.contributor | Hemmings, Robert | - |
item.contributor | Masood, Aisha | - |
item.contributor | Newsome, Simon | - |
item.contributor | Saxton, Claire | - |
item.contributor | Warwick, Lorna | - |
item.contributor | Yateman, Nigel A. | - |
item.contributor | Zuber, Emmanuel | - |
crisitem.journal.issn | 1479-6694 | - |
crisitem.journal.eissn | 1744-8301 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
End points in clinical trials in diffuse large B-cell lymphoma time for more dialogue .pdf | Early view | 1.84 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.